WFH/LinkedIn
Sep 18, 2025, 09:18
WFH Vice President Glenn Pierce on Slow Uptake and Industry Shifts in Hemophilia Gene Therapy
The World Federation of Hemophilia (WFH) posted on LinkedIn:
”WFH Vice President, Medical, Glenn Pierce, joins Zoey Becker in this week’s episode of The Top Line, to unpack the complex reality of Gene Therapy for hemophilia. Pierce discusses why the uptake remains slow, what led to some pharma companies exit and who risks being left behind in this evolving landscape.
Listen now.”
Stay updated with Hemostasis Today.
-
Nov 19, 2026, 05:40Pete Stibbs: Advancing Treatment Strategies in Venous Disease
-
Nov 19, 2026, 05:31Lance Reed: One Donation, Multiple Lives
-
Nov 19, 2026, 05:20ZPI Silencing as a Novel Non-Factor Therapy for Rare Bleeding Disorders – HITh
-
Nov 19, 2026, 04:48Antiphospholipid Antibodies and Stroke Management – RPTH
-
Nov 18, 2026, 20:58Uma Vaidyanathan: When Hemoglobin Does Not Respond to Iron Therapy, Look Beyond Iron Deficiency
-
Nov 18, 2026, 20:57Jamil Rafiq: 5 Ways to Prevent Sample Haemolysis
-
Nov 18, 2026, 20:55Nasir Jamal: Plasmapheresis – Key Concepts at a Glance
-
Nov 18, 2026, 20:55Tarık Seller: Pulmonary Embolism – When a Blood Clot Becomes a Life-Threatening Emergency
-
Nov 18, 2026, 20:53Sandya Arunachalam: Bringing the Profession Together at the Haemostasis and Thrombosis Workshop